文献速递神经MR

评估钆基对比剂与帕金森病之间的关联:来自韩国国民健康保险服务数据库的洞察

Assessing the Association Between Gadolinium-Based Contrast Agents and Parkinson Disease: Insights From the Korean National Health Insurance Service Database.
PubMed 文献 · Invest Radiol · 2025-01-23

本研究基于韩国国民健康保险服务数据库的回顾性队列,纳入175125名40至60岁无脑病史成人,其中至少使用过一次钆基对比剂者3835例,随访至2022年观察帕金森病发生。倾向评分匹配后,线性钆基对比剂组帕金森病发生率0.9%高于无钆基对比剂组的0.0%(P=0.002),大环状钆基对比剂组0.5%也高于无钆基对比剂组的0.04%(P=0.003);线性与大环状钆基对比剂两组间帕金森病发生率无显著差异。

要点

  • 倾向评分匹配后,线性钆基对比剂组帕金森病发生率0.9%,无钆基对比剂组0.0%(P=0.002)。
  • 大环状钆基对比剂组帕金森病发生率0.5%,无钆基对比剂组0.04%(P=0.003)。
  • 线性与大环状钆基对比剂两组间帕金森病发生率无显著差异。

核心结论

  • 在这项大型人群研究中,钆基对比剂暴露与帕金森病风险升高相关;线性与大环状钆基对比剂的帕金森病风险无显著差异。

研究设计与样本

  • 回顾性队列研究,数据来自韩国国民健康保险服务数据库,共1,038,439人,其中175,125名40至60岁无脑病史成人纳入分析,3,835人至少使用过一次钆基对比剂,随访至2022年观察帕金森病发生,采用倾向评分匹配比较暴露组与未暴露组。

诊断标准与关键数值

  • 倾向评分匹配后,线性钆基对比剂组帕金森病发生率为0.9%,无钆基对比剂组为0.0%(P=0.002)。
  • 倾向评分匹配后,大环状钆基对比剂组帕金森病发生率为0.5%,无钆基对比剂组为0.04%(P=0.003)。
  • 线性钆基对比剂组与大环状钆基对比剂组之间帕金森病发生率无显著差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: This study aimed to investigate the association between the use of linear and macrocyclic gadolinium-based contrast agents (GBCAs) and the subsequent development of Parkinson disease (PD).

METHODS: In this retrospective cohort study, data were extracted from the Korean National Health Insurance Service database, comprising 1,038,439 individuals. From this population, 175,125 adults aged 40 to 60 years with no history of brain disease were identified. All patients including 3835 who were administered GBCA at least once were monitored until 2022 for the onset of PD. Propensity score (PS) matching was employed to compare the incidence of PD between those exposed to GBCAs (either linear or macrocyclic) and those not exposed (no-GBCA group).

RESULTS: The final cohort consisted of 1175 subjects exposed to linear GBCAs, 2334 exposed to macrocyclic GBCAs, and 171,616 unexposed to any GBCA (no-GBCA group). After PS matching, PD incidence was significantly higher in the linear GBCA group compared with the no-GBCA group (0.9% vs 0.0%, P = 0.002) and was also significantly higher in the macrocyclic GBCA group than in the no-GBCA group (0.5% vs 0.04%, P = 0.003). No significant difference in PD incidence was observed between the linear and macrocyclic GBCA groups.

CONCLUSIONS: Exposure to GBCAs was linked to an increased risk of developing PD in this large population-based study. The risk of PD did not differ significantly between linear and macrocyclic GBCAs.

来源:Invest Radiol,查看原文。版权归原作者所有。

引用

  1. Kim C, Kim C, Tae BS, et al. Assessing the Association Between Gadolinium-Based Contrast Agents and Parkinson Disease: Insights From the Korean National Health Insurance Service Database. Invest Radiol. 2025. PMID: 39841176. doi:10.1097/RLI.0000000000001155

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。